For medical devices in the Breakthrough Devices Program, 2022 has been a breakout year.
The Food and Drug Administration is on track to top its previous records, offering expedited regulatory consideration — and if medical device companies have their way, a streamlined path to insurance coverage — to dozens of novel tools.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
